Stay updated with breaking news from John Farley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year old in the United States every year.
This fall, for the first time many babies in the U.S. will be able to get a shot to fend off RSV, a respiratory virus that can cause serious lung disease in infants and young children.
This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year old in the United States every year.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
The US Food and Drug Administration approved nirsevimab to protect newborns from respiratory syncytial virus, or RSV, on Monday.